Brokerage firm Barclays Maintains its rating on Ironwood Pharmaceuticals(NASDAQ:IRWD). In a research note issued to the investors, the brokerage major Raises the price-target to $12.00 per share. The shares have been rated Equal-weight. The rating by Barclays was issued on Aug 5, 2016.
Ironwood Pharmaceuticals (IRWD) made into the market gainers list on Wednesdays trading session with the shares advancing 0.60% or 0.08 points. Due to strong positive momentum, the stock ended at $13.4, which is also near the day’s high of $13.44. The stock began the session at $13.27 and the volume stood at 5,85,665 shares. The 52-week high of the shares is $14.78 and the 52 week low is $7.35. The company has a current market capitalization of $1,947 M and it has 14,53,18,600 shares in outstanding.
Ironwood Pharmaceuticals(IRWD) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $54.35M. Analysts had an estimated revenue of $54.49M. Earnings per share were $-0.16. Analysts had estimated an EPS of $-0.17.
Several Insider Transactions has been reported to the SEC. On Jun 6, 2016, Lawrence S Olanoff (director) sold 2,200 shares at $12.92 per share price.Also, On May 27, 2016, Halley E Gilbert (Chief Legal Officer) sold 20,275 shares at $12.19 per share price.On Mar 11, 2016, Peter M Hecht (Chief Executive Officer) sold 120,000 shares at $10.72 per share price, according to the Form-4 filing with the securities and exchange commission.
Ironwood Pharmaceuticals Inc. is a pharmaceutical company. The Company has a product linaclotide which is available in the United States and Mexico under the brand name LINZESS and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.